None of the participants experienced grade 3 or 4 side effects.
The world has come a long way in the fight against HIV; of course, one of the biggest advancements made came with the advent of antiretroviral therapy (ART), which offers infected individuals treatment options that would allow them to live longer, healthier lives, and helps reduce their risk of transmission.
Researchers are constantly working to improve treatment strategies in efforts to increase adherence, reduce associated toxicity and costs, and to try to stay ahead of resistant strains of the virus. As such, dual therapies that do not use nucleoside reverse transcriptase inhibitors (NRTIs, or sometimes referred to as “nukes”) are being explored and appear promising.
At the 25th Conference on Retroviruses and Opportunistic Infections (CROI), Emilie Elliot, from the Chelsea and Westminster Hospital in London, United Kingdom, presented a poster regarding research that explored the pharmacokinetics of dolutegravir (ViiV Healthcare's Tivicay) with and without darunavir/cobicistat (Janssen's Prezcobix) in healthy volunteers.
“The integrase inhibitor, dolutegravir (DTG), combined with boosted darunavir (DRV), both potent and with high resistance barriers, potentially offers a powerful yet safe and tolerable ART dual therapy regimen,” study authors write.
For more information, please visit ContagionLive.com.